Loading…
← CockpitCompetitor Analysis › REG.AX Regis Healthcare Ltd.Open in the cockpit ↗

Regis Healthcare Ltd.REG.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Medical/Nursing Services
Momentum weak 20
Mkt cap
$962M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$1.56M
20-day average traded
Fwd P/E
25.3×
forward earnings
ROIC−WACC
n/a
WACC 11.8%
Hurdle
-1 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · AUDA$4.65
1D-3.1%
1W-7.9%
1M+0.9%
3M-27.2%
6M-27.9%
YTD-33.1%
1Y-35.7%
ATR %3.3%
52w lowhigh43.3% off high

What Regis Healthcare does

Employees: 13,000

Regis Healthcare at a glance

Size Regis Healthcare (REG.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $962M, the 177th largest of 317 Australia companies the cockpit tracks. Shares closed at A$4.65 on 18 Nov 2026.

Performance Over six months the shares fell 27.9%, against +0.9% for the median peer and +1.2% for the Australia market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 16.6% over the last twelve months (peer median +6.2%); the operating margin is 3.8% (peer median 7.6%).

Valuation It trades at 25.3× forward earnings against a peer median of 19.5× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -1 pp: the price already allows for a slowdown.

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 105REG.AX 72
Six months, rebased to 100: Regis Healthcare against the median of its 20 peers (local-currency closes).

Regis Healthcare financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$1.34BA$1.34BA$1.15BA$1.01BA$771M
Revenue growth—+17%+15%+30%—
Gross profitA$153MA$153MA$141MA$39.0M-A$3.78M
EBITDAA$107MA$107MA$101MA$83.6MA$50.1M
Net incomeA$55.7MA$55.7MA$49.0M-A$21.4M-A$28.5M
Free cash flowA$194MA$194MA$220MA$187MA$53.7M
Capital expenditureA$142MA$142MA$86.5MA$65.7MA$51.4M
Total debtn/aA$3.99MA$5.11MA$3.84MA$71.1M

Quarterly statements and history in the cockpit →

Regis Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%4694AHCO688315THYROCARETTALOGDRX195940NUTX1951METROPOLISOPKPNTGDIACLARINEPHROPLUSFLGTLMRI1833WELLREG.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Regis Healthcare is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×4694688315THYROCARETTALOGDRX195940NUTX1951METROPOLISPNTGDIAGMRSCLARINEPHROPLUSLMRI1833WELLREG.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Regis Healthcare is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%4694AHCOTHYROCARETTALOGDRXNUTXGMRSWELLREG.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Regis Healthcare is the large dot.

Regis Healthcare competitors and peer comparison

How Regis Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Regis Healthcare against its 20 peers (data as of 18 Nov 2026)
MeasureREG.AXPeer medianRank in peer set
1-month return+0.9%+2.0%9th lowest of 21
6-month return-27.9%+0.9%4th lowest of 21
Distance from 52-week high-43.3%-24.0%3rd lowest of 21
Revenue growth (TTM)+16.6%+6.2%7th highest of 21
Operating margin3.8%7.6%6th lowest of 21
Forward P/E25.3×19.5×6th most expensive of 18
Growth the price implies (Req g, 7 yrs)13.3%7.3%8th most demanding of 18
Growth delivered (Del g)+14.4%+10.9%7th highest of 18
Hurdle (Req g minus delivered)-1.1 pp-1.4 pp9th most demanding of 18
EV / EBITDA11.8×8.7×6th most expensive of 17
Net debt / EBITDA-1.6×2.0×3rd least indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%16.0×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%33.5×3.5%-5.1%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%

Questions

Which companies are Regis Healthcare's closest peers?
The cockpit's peer set: BML (4694.T), AdaptHealth (AHCO), Novogene (688315.SS), Thyrocare Technologies (THYROCARE.NS), Terveystalo Oy (TTALO.HE), GoodRx (GDRX), HK inno.N (195940.KS), Nutex Health (NUTX).
Is Regis Healthcare expensive compared with its peers?
On forward p/e it trades at 25.3× against a peer median of 19.5×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -1 pp: the price already allows for a slowdown.
How has Regis Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned -27.9% against +0.9% for the median peer; over one year -35.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.